Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

Linda Stein Gold; Melinda Gooderham; Kim Papp; Laura Ferris; Mark Lebwohl; David Adam; Javier  Alonso-Llamazares; Chih-ho Hong; Steve Kempers; Leon  Kircik; Wei Jing Loo; Daniel Stewart; Walter Nahm; Matthew Zirwas; Patrick Burnett; Robert Higham; Lynn Navale; David Berk

doi:10.25251/skin.5.supp.44

Linda Stein Gold

Henry Ford Health System, Detroit, MI, USA

Melinda Gooderham

SkiN Centre for Dermatology, Probity Medical Research and Queen’s University, Peterborough, ON, Canada

Kim Papp

Probity Medical Research, Waterloo, ON, Canada

Laura Ferris

University of Pittsburgh, Department of Dermatology, Pittsburgh, PA, USA

Mark Lebwohl

Mount Sinai

David Adam

CCA Medical Research, Probity Medical Research and Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

Javier Alonso-Llamazares

Driven Research LLC, Coral Gables, FL, USA

Chih-ho Hong

Probity Medical Research and University of British Columbia, Department of Dermatology and Skin Science, Surrey, BC, Canada

Steve Kempers

Minnesota Clinical Study Center, Fridley, MN, USA

Leon Kircik

Mount Sinai

Wei Jing Loo

DermEffects, London, ON, Canada

Daniel Stewart

Michigan Center for Skin Care Research, Clinton Township, MI, USA

Walter Nahm

University of California, San Diego, School of Medicine

Matthew Zirwas

Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA

Patrick Burnett

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Robert Higham

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Lynn Navale

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

David Berk

Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Keywords

roflumilast, psoriasis, phase 2b study

Abstract

N/A

References

1. Dong C, et al. J Pharmacol Exp Ther 2016;358:413-422.

2. Lebwohl MG, et al. N Engl J Med 2020;383:229-239

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.44

How to Cite

Stein Gold, L., Gooderham, M., Papp, K., Ferris, L., Lebwohl, M., Adam, D., Alonso-Llamazares, J. ., Hong, C.- ho, Kempers, S., Kircik, L. ., Jing Loo, W., Stewart, D., Nahm, W., Zirwas, M., Burnett, P., Higham, R., Navale, L., & Berk, D. (2021). Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study. SKIN The Journal of Cutaneous Medicine, 5(6), s44. https://doi.org/10.25251/skin.5.supp.44

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Poster Presentations from FC21 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Brian Berman, Roger Ceilley, Clay Cockerell, Laura Ferris, Whitney A High, Mark Lebwohl, Mark S Nestor, Theodore Rosen, Graham H Litchman, Giselle Prado, Ryan M Svoboda, Darrell S Rigel, Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 5 (2019)
Matthew S Dinehart, Stacy McMurray, Scott M Dinehart, Mark Lebwohl, L-Carnitine Reduces Muscle Cramps in Patients taking Vismodegib , SKIN The Journal of Cutaneous Medicine: Vol. 2 No. 2 (2018)
Sophie Guenin, Emily Elbogen , Mindy Kresch , Mark Lebwohl , Herpes Zoster Post-COVID-19 Vaccination in Young Adults (Under 35) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Ali Hadi, Mark Lebwohl, Apremilast for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case Series , SKIN The Journal of Cutaneous Medicine: Vol. 1 No. 1 (2017)
Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Justin W. Marson, Mark Lebwohl, Apremilast as an Off-Label Therapeutic Agent , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 3 (2021)
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson, Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Brook Brouha, Laura Ferris, Maral Skelsey, Gary Peck, Jim Rock, Anh Nguyen, Zuxu Yao, Michael Howell, Burkhard Jansen, Clay Cockerell, Genomic Atypia to Enrich Melanoma Positivity in Biopsied Lesions: Gene Expression and Pathology Findings From a Large U.S. Registry Study , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Danny Zakria, Nicholas Brownstone, Brian Berman, Roger Ceilley, Gary Goldenberg, Mark Lebwohl, Graham Litchman, Daniel Siegel, Incorporating Prognostic Gene Expression Profile Assays into the Management of Cutaneous Melanoma: An Expert Consensus Panel Report , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 1 (2023)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)